Sökning: id:"swepub:oai:DiVA.org:uu-155929" >
Success Story of Ta...
Success Story of Targeted Therapy in Chronic Myeloid Leukemia : A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
-
- Björkholm, Magnus (författare)
- Karolinska Institutet
-
Ohm, Lotta (författare)
-
- Eloranta, Sandra (författare)
- Karolinska Institutet
-
visa fler...
-
- Derolf, Åsa (författare)
- Karolinska Institutet
-
- Hultcrantz, Malin (författare)
- Karolinska Institutet
-
Sjöberg, Jan (författare)
-
- Andersson, Therese (författare)
- Karolinska Institutet
-
- Höglund, Martin (författare)
- Uppsala universitet,Medicin,Hematologi
-
- Richter, Johan (författare)
- Lund University,Lunds universitet,Avdelningen för molekylärmedicin och genterapi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Molecular Medicine and Gene Therapy,Department of Laboratory Medicine,Faculty of Medicine
-
Landgren, Ola (författare)
-
- Kristinsson, Sigurdur Y. (författare)
- Karolinska Institutet
-
- Dickman, Paul W. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2011
- 2011
- Engelska.
-
Ingår i: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 29:18, s. 2514-2520
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Purpose Chronic myeloid leukemia (CML) management changed dramatically with the development of imatinib mesylate (IM), the first tyrosine kinase inhibitor targeting the BCR-ABL1 oncoprotein. In Sweden, the drug was approved in November 2001. We report relative survival (RS) of patients with CML diagnosed during a 36-year period. Patients and Methods Using data from the population-based Swedish Cancer Registry and population life tables, we estimated RS for all patients diagnosed with CML from 1973 to 2008 (n = 3,173; 1,796 males and 1,377 females; median age, 62 years). Patients were categorized into five age groups and five calendar periods, the last being 2001 to 2008. Information on use of upfront IM was collected from the Swedish CML registry. Results Relative survival improved with each calendar period, with the greatest improvement between 1994-2000 and 2001-2008. Five-year cumulative relative survival ratios (95% CIs) were 0.21 (0.17 to 0.24) for patients diagnosed 1973-1979, 0.54 (0.50 to 0.58) for 1994-2000, and 0.80 (0.75 to 0.83) for 2001-2008. This improvement was confined to patients younger than 79 years of age. Five-year RSRs for patients diagnosed from 2001 to 2008 were 0.91 (95% CI, 0.85 to 0.94) and 0.25 (95% CI, 0.10 to 0.47) for patients younger than 50 and older than 79 years, respectively. Men had inferior outcome. Upfront overall use of IM increased from 40% (2002) to 84% (2006). Only 18% of patients older than 80 years of age received IM as first-line therapy. Conclusion This large population-based study shows a major improvement in outcome of patients with CML up to 79 years of age diagnosed from 2001 to 2008, mainly caused by an increasing use of IM. The elderly still have poorer outcome, partly because of a limited use of IM.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Björkholm, Magnu ...
-
Ohm, Lotta
-
Eloranta, Sandra
-
Derolf, Åsa
-
Hultcrantz, Mali ...
-
Sjöberg, Jan
-
visa fler...
-
Andersson, There ...
-
Höglund, Martin
-
Richter, Johan
-
Landgren, Ola
-
Kristinsson, Sig ...
-
Dickman, Paul W.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet